Efficacy of Vonoprazan for Helicobacter pylori Eradication
- PMID: 31243237
- PMCID: PMC7008041
- DOI: 10.2169/internalmedicine.2521-18
Efficacy of Vonoprazan for Helicobacter pylori Eradication
Abstract
Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available.
Keywords: Helicobacter pylori; eradication; potassium-competitive acid blocker (P-CAB); proton pump inhibitor (PPI); vonoprazan.
Conflict of interest statement
Similar articles
-
Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.J Dig Dis. 2016 Oct;17(10):670-675. doi: 10.1111/1751-2980.12398. J Dig Dis. 2016. PMID: 27534444
-
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.Ann Clin Microbiol Antimicrob. 2018 Jun 28;17(1):29. doi: 10.1186/s12941-018-0281-x. Ann Clin Microbiol Antimicrob. 2018. PMID: 29950163 Free PMC article.
-
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.Dig Dis Sci. 2016 Nov;61(11):3215-3220. doi: 10.1007/s10620-016-4305-0. Epub 2016 Sep 22. Dig Dis Sci. 2016. PMID: 27659671
-
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.Helicobacter. 2018 Aug;23(4):e12495. doi: 10.1111/hel.12495. Epub 2018 Jun 6. Helicobacter. 2018. PMID: 29873436
-
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Dig Dis Sci. 2017 Nov;62(11):3069-3076. doi: 10.1007/s10620-017-4664-1. Epub 2017 Jun 29. Dig Dis Sci. 2017. PMID: 28664410 Review.
Cited by
-
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy.Pharmaceuticals (Basel). 2020 Sep 28;13(10):276. doi: 10.3390/ph13100276. Pharmaceuticals (Basel). 2020. PMID: 32998241 Free PMC article. Review.
-
Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.J Gastroenterol. 2020 Nov;55(11):1054-1061. doi: 10.1007/s00535-020-01723-6. Epub 2020 Sep 15. J Gastroenterol. 2020. PMID: 32930864
-
Helicobacter pylori Eradication Treatment in Older Patients.Drugs Aging. 2024 Feb;41(2):141-151. doi: 10.1007/s40266-023-01090-w. Epub 2024 Feb 10. Drugs Aging. 2024. PMID: 38340290 Review.
-
Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349. World J Clin Cases. 2022. PMID: 35979311 Free PMC article. Review.
-
Biodegradable Guar-Gum-Based Super-Porous Matrices for Gastroretentive Controlled Drug Release in the Treatment of Helicobacter pylori: A Proof of Concept.Int J Mol Sci. 2023 Jan 23;24(3):2281. doi: 10.3390/ijms24032281. Int J Mol Sci. 2023. PMID: 36768604 Free PMC article.
References
-
- Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1: 1273-1275, 1983. - PubMed
-
- Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142: 436-439, 1985. - PubMed
-
- Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82: 192-199, 1987. - PubMed
-
- Asaka M, Kato M, Kudo M, et al. . Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1: 52-56, 1996. - PubMed
-
- Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12 (Suppl 2): 32-38, 2007. - PubMed